As a physician-scientist and medical oncologist, being a healer is at Isaac Klein's core – his driving purpose is to improve lives through science. Throughout his career, Isaac has sought to deploy novel biology and technology to better understand human disease and guide therapeutic development. He has extensively studied the intersection of condensate science, cell biology and pathophysiology with the goal of unlocking the potential of new science to deliver life-changing medicines for patients.
Joining Dewpoint as Chief Scientific Officer gave Isaac the opportunity of a lifetime – to realize his aspiration of shepherding a scientific concept from the laboratory bench to the patient’s bedside. Prior to joining Dewpoint, Isaac was on the faculty at the Dana Farber Cancer Institute and Harvard Medical School, as well as a scientist at the Whitehead Institute of the Massachusetts Institute of Technology. He was an undergraduate at Cornell University in the Department of Biological and Agricultural Engineering. He holds a Ph.D. in Biology from The Rockefeller University and an MD from Weill Cornell Medical College. He trained in Internal Medicine at the Brigham and Women’s Hospital of Harvard Medical School, and in Medical Oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital. In 2022, Isaac was named one of Endpoints News 20 under 40 in Biopharma.
Joining Dewpoint as Chief Scientific Officer gave Isaac the opportunity of a lifetime – to realize his aspiration of shepherding a scientific concept from the laboratory bench to the patient’s bedside. Prior to joining Dewpoint, Isaac was on the faculty at the Dana Farber Cancer Institute and Harvard Medical School, as well as a scientist at the Whitehead Institute of the Massachusetts Institute of Technology. He was an undergraduate at Cornell University in the Department of Biological and Agricultural Engineering. He holds a Ph.D. in Biology from The Rockefeller University and an MD from Weill Cornell Medical College. He trained in Internal Medicine at the Brigham and Women’s Hospital of Harvard Medical School, and in Medical Oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital. In 2022, Isaac was named one of Endpoints News 20 under 40 in Biopharma.
Speaking In
3:00 PM - 4:00 PM
Tuesday, June 6
